The Food and Drug Administration (FDA) yesterday announced emergency use authorization (EUA) standards for locally developed COVID-19 vaccines, just hours before Medigen Vaccine Biologics Corp (高端) announced its phase 2 trial results.
The standards include safety data from at least 3,000 subjects and efficacy test results at least on par with the AstraZeneca vaccine, the FDA said.
The standards were determined after a year of discussions with experts in the clinical, statistical, pharmaceutical, manufacturing, public health and other related fields, it added.
Photo: Huang Mei-chu, Taipei Times
The EUA review is to focus on two main points: safety and efficacy, Medical Products Division deputy head Wu Ming-mei (吳明美) told reporters.
Efficacy would be difficult to assess, as clinical trials were held while Taiwan did not have any community transmission, Wu said.
This means the subjects did not have contact with the virus, making it less clear whether the vaccine had the intended effect compared with the control group, she added.
The review would therefore refer to a criteria the WHO began discussing earlier this year called immunogenicity, which measures the type of immune responses triggered by a vaccine and their magnitude over time, she said.
This would involve measuring the level, or titer, of neutralizing antibodies in the body after vaccination to determine efficacy, she added.
To determine the appropriate level, the FDA is to commission Ministry of Health and Welfare hospitals to conduct studies comparing the effect of domestic vaccines with that of foreign vaccines, Wu said.
Researchers are to put together a control group of 200 Taiwanese who have received both doses of the AstraZeneca vaccine since rollout began in March, she said.
If the neutralizing antibody titer among subjects who received the domestic vaccine are at least as high as that of the control group, then the vaccine would be considered effective, she added.
As for the safety part of the evaluation, the FDA would require researchers to follow up with 3,000 or more clinical trial participants for at least one month after receiving their last dose, Wu said.
The report must then compile safety data from the subjects followed for a median of at least two months, she said, adding that it must include a population study for people older than 65.
Medigen was yesterday set to unblind participants of the second stage of clinical trials for its COVID-19 vaccine, leading some to speculate over potential insights into its efficacy.
The unblinding would only reveal if there were differences between the subjects who received a vaccine and those who received a placebo, Wu said.
The results must still be sent to the FDA before it can begin EUA procedures, she added.
MEDIGEN: The vaccine must also be reviewed by the Advisory Committee on Immunization Practices before it is added to the national vaccination program An emergency use authorization (EUA) for Medigen Vaccine Biologics Corp’s (高端疫苗) COVID-19 vaccine — MVC-COV1901 — for people aged 20 and older was issued by the Food and Drug Administration (FDA) yesterday. Minister of Health and Welfare Chen Shih-chung (陳時中) said a specialists’ meeting was held at the FDA on Sunday to review Medigen’s application to manufacture and distribute its COVID-19 vaccine, and the panel approved it. FDA Director Wu Hsiu-mei (吳秀梅) said the meeting consisted of 21 specialists from the fields of chemistry, manufacturing and controls, pharmacy, toxicology, clinical medicine, public health, law and medical ethics. There were no major concerns over
LAND ALERT UNCERTAIN: The CWB was waiting to observe how In-Fa shifts as it moves north to determine when to issue a land alert, a forecaster at the bureau said Residents of northern Taiwan should brace for heavy rain today and tomorrow as Typhoon In-Fa approaches the northeast, the Central Weather Bureau (CWB) said yesterday. A land alert for the typhoon would be issued depending on the angle at which it moves north today, the bureau said. The bureau on Wednesday issued a sea alert for the typhoon, which applies to ships operating off the nation’s northern, northeastern and southeastern coasts. As of 8:30pm yesterday, In-Fa’s center was 470km southeast of Taipei, moving northwest at 6kph. It was carrying maximum sustained winds of 180kph, and had a radius of 200km. The typhoon was moving
‘BREAKTHROUGH’: All countries should be free to pursue closer ties with Taiwan, a leading democracy, a major economy, and a force for good in the world, the AIT said Taiwan is to establish a “Taiwanese Representative Office in Lithuania,” the first office in Europe to be called Taiwanese, the Ministry of Foreign Affairs announced yesterday. “It is an important diplomatic breakthrough,” President Tsai Ing-wen (蔡英文) wrote on Facebook, thanking diplomatic personnel for the significant achievement. To expand the nation’s relations with central and eastern Europe, especially with Baltic nations, the government decided to establish the office in Vilnius, Minister of Foreign Affairs Joseph Wu (吳釗燮) told an online news conference. The plan signals progress in Taiwan-Europe relations, as it has been 18 years since the nation last opened an office on the
TARGET RAISED: The CECC said vaccination coverage has reached 24.35%, while Premier Su Tseng-chang said the government hopes for 30% by the end of July The government has signed a contract to buy an additional 36 million doses of the Moderna COVID-19 vaccine, 1 million of which are to be delivered in the fourth quarter, the Executive Yuan announced yesterday, as it updated its vaccination target to 30 percent coverage by the end of the month. The two-year deal with the US company covers “prime series” vaccines and future booster shots to protect against SARS-CoV-2 variants, Executive Yuan spokesman Lo Ping-cheng (羅秉成) quoted Premier Su Tseng-chang (蘇貞昌) as saying during an Executive Yuan meeting in Taipei. In the two weeks since vaccine registration opened, more than 9.8